202 related articles for article (PubMed ID: 38746435)
1. Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer.
Ishov A; Sarwar S; Morozov V; Newcomb M; Guryanova O
Res Sq; 2024 Apr; ():. PubMed ID: 38746435
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer.
Sarwar S; Morozov VM; Purayil H; Daaka Y; Ishov AM
Cell Death Dis; 2022 Oct; 13(10):868. PubMed ID: 36229449
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
[TBL] [Abstract][Full Text] [Related]
4. The Andrographolide Analogue 3A.1 Synergizes with Taxane Derivatives in Aggressive Metastatic Prostate Cancers by Upregulation of Heat Shock Proteins and Downregulation of MAT2A-Mediated Cell Migration and Invasion.
Mitra Ghosh T; Kansom T; Mazumder S; Davis J; Alnaim AS; Jasper SL; Zhang C; Bird A; Opanasopit P; Mitra AK; Arnold RD
J Pharmacol Exp Ther; 2022 Mar; 380(3):180-201. PubMed ID: 34949650
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer.
Lima TS; Souza LO; Iglesias-Gato D; Elversang J; Jørgensen FS; Kallunki T; Røder MA; Brasso K; Moreira JMA
Front Pharmacol; 2022; 13():869461. PubMed ID: 35721223
[TBL] [Abstract][Full Text] [Related]
6. Activation of the
Lombard AP; Lou W; Armstrong CM; D'Abronzo LS; Ning S; Evans CP; Gao AC
Mol Cancer Ther; 2021 Oct; 20(10):2061-2070. PubMed ID: 34326198
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines.
Linke D; Donix L; Peitzsch C; Erb HHH; Dubrovska A; Pfeifer M; Thomas C; Fuessel S; Erdmann K
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614114
[TBL] [Abstract][Full Text] [Related]
8. Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer.
Francini E; Ou FS; Rhoades J; Wolfe EG; O'Connor EP; Ha G; Gydush G; Kelleher KM; Bhatt RS; Balk SP; Sweeney CJ; Adalsteinsson VA; Taplin ME; Choudhury AD
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439209
[TBL] [Abstract][Full Text] [Related]
9. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes.
Ríos-Colón L; Cajigas-Du Ross CK; Basu A; Elix C; Alicea-Polanco I; Sanchez TW; Radhakrishnan V; Chen CS; Casiano CA
Oncotarget; 2017 Apr; 8(15):24915-24931. PubMed ID: 28212536
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.
Zhu Y; Liu C; Nadiminty N; Lou W; Tummala R; Evans CP; Gao AC
Mol Cancer Ther; 2013 Sep; 12(9):1829-36. PubMed ID: 23861346
[TBL] [Abstract][Full Text] [Related]
12. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Chao OS; Goodman OB
Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
[TBL] [Abstract][Full Text] [Related]
13. Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate Cancer.
Qian S; Zhang S; Wu Y; Ding Y; ; Li X
Chemotherapy; 2020; 65(5-6):125-133. PubMed ID: 33238278
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
[TBL] [Abstract][Full Text] [Related]
15. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
Sekino Y; Han X; Kawaguchi T; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Yasui W; Matsubara A
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412591
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
17. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer.
Schaaf ZA; Ning S; Leslie AR; Sharifi M; Han X; Armstrong C; Lou W; Lombard AP; Liu C; Gao AC
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958444
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs.
Wang Y; Huang Z; Chen CZ; Liu C; Evans CP; Gao AC; Zhou F; Chen HW
Mol Cancer Ther; 2020 Feb; 19(2):364-374. PubMed ID: 31712394
[TBL] [Abstract][Full Text] [Related]
20. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]